leisure time -WSS

leisure time

author：explore 2025-09-06 01:59:08 - browse：7

An army of wooden figures under blue and pink lighting — biotech coverage from STAT — Adobe

In an abrupt change of course from plans earlier in the month, at-home test maker Cue Health is laying off all of its employees and shutting down as of Friday, May 24.

The company, which grew to prominence during the Covid-19 pandemic as the maker of one of the only molecular at-home tests for the virus, has been teetering on the edge of insolvency for months. The shutdown, first reported by the San Diego Union-Tribune, comes just over a week after the FDA warned consumers not to use Cue’s only FDA-authorized product, a Covid-19 test kit.

Cue had previously notified 49% of its workers on May 1 that they would be laid off from the company, effective July 1. But in a WARN notice filed with California state regulators on May 20, chief human resources officer Allison Blackwell said that due to the “fluid nature of this situation,” all U.S. employees who had not already received notice of termination would be receiving one. All employees will receive their last paychecks on May 24, the notice said.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Crowdfunding for unproven stem cell procedures spreads misinformation

focus

WSS

UpToDate has a racism problem: Dr. Stanley Goldfarb

'Screen and refer' systems are hurting patients

Senators tussle over abortion against the backdrop of a presidential campaign

ASCO Takeaways: Winners, snoozers, and the art of cancer care

Undocumented workers face uncertainty as immigration law takes effect in Florida

Vertex cell therapy lets patients with type 1 diabetes stop insulin

leisure time

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

New air purifier tech could be key to improving indoor air quality

Fatty liver disease was alleviated by Lilly’s ‘triple

Trump demands the U.S. pay no more for drugs than other countries … again

A letter from the executive editor: The 2023 STATUS List

In age of alternative facts, a scholarly course on calling out crap

ASCO Daily Recap: CAR

Activists slam private health insurers over coverage restrictions

Stopping antidepressants leads to symptoms for 1 in 6 patients

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Security flaws in third

Wikipedia

Eli Lilly’s Zepbound improved liver scarring in mid

Structure Therapeutics oral GLP

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

CMS got Medicare Advantage quality rating wrong, judge rules

Fatty liver disease was alleviated by Lilly’s ‘triple

Drug cartel violence flares in western Mexico after vigilante leader's killing

hotspot

focus

hotspot

focus